Aldosterone plays crusial role in rening-angiontenzin-aldosterone system regulation. It promotes heart failure by binding to mineralcorticoid receptors. Mineralcorticoid receptors antagonists are effective pathogenetic treatment of cardiovascular disease. But what patient subgroups get benefit more from the treatment?
In the new program of series "Heart failure: game of chess, strategy of play", Professor John McMurray from University of Glasgow, Scotland, is going to shed light on these patient subgroups differences from the standpoint of evidence-based medicine.